Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
|Pulmonary Arterial Hypertension||Drug: treprostinil Device: Crono Five ambulatory pump||Phase 4|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) Using the Crono Five Ambulatory Infusion Pump in Patients With Stable Pulmonary Arterial Hypertension (PAH): Safety, Efficacy and Treatment Satisfaction|
- Change From Baseline at Week 8 in 6-Minute Walk Distance (6MWD) [ Time Frame: Week 8 ]The administration of the 6MWD test and specifications of the testing area were consistent with the American Thoracic Society guidelines and the usual practice of the investigative site [American Thoracic Society (ATS) guidelines; 2002].
- Change From Baseline at Week 8 in Borg Dyspnea Score Immediately After Six Minute Walk Test [ Time Frame: Week 8 ]The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).
- Change From Baseline at Week 8 in World Health Organization (WHO) Functional Classification [ Time Frame: Week 8 ]WHO functional class is a system to help clinicians determine how limited a patient is in their ability to do the activities of daily living. The scale ranges from class I to class IV. In general, patients with more severe Pulmonary Hypertension (PH) tend to have a higher functional class.
- Change From Baseline at Week 8 in Symptoms of PAH- Fatigue [ Time Frame: Week 8 ]The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.
- Change From Baseline at Week 8 in Symptoms of PAH- Dyspnea [ Time Frame: Week 8 ]The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.
- Change From Baseline at Week 8 in Symptoms of PAH- Edema [ Time Frame: Week 8 ]The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.
- Change From Baseline at Week 8 in PAH Symptoms- Orthopnea [ Time Frame: Week 8 ]The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.
- Change From Baseline at Week 8 in PAH Symptoms- Dizziness [ Time Frame: Week 8 ]The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.
- Change From Baseline at Week 8 in PAH Symptoms- Syncope [ Time Frame: Week 8 ]The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.
- Change From Baseline at Week 8 in PAH Symptoms- Chest Pain [ Time Frame: Week 8 ]The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.
- Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol [ Time Frame: Week 8 ]A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin.
- Change From Baseline at Week 8 in Score on Quality of Life (QOL) Questionnaire - The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) [ Time Frame: Baseline and Week 8 ]The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and QOL. The CAMPHOR was completed at Baseline and at Week 8. The CAMPHOR consists of 3 scales: 1. A 25-item overall symptoms scale scored 0-25, with a higher score indicating the presence of more symptoms. 2. A 15 item Activity/Functioning scale scored 0-30, where a low score indicates good functioning. 3. A 25-item QoL scale scored 0-25, with a high score indicating poor QoL. Additionally, a total score was recorded by adding up the the scores from the 3 above scales. The Symptom and QoL scales have dichotomous ('True'/'Not true') response options while the Activity/Functioning scale has three-point ('Able to do on own without difficulty'/'Able to do on own with difficulty'/'Unable to do on own') response options. Reduction in score denotes improved heath status.
- Change From Baseline at Week 8 in Score on Treatment Satisfaction Questionnaire- The Treatment Satisfaction Questionnaire for Medication (TSQM) [ Time Frame: Baseline and Week 8 ]The Treatment Satisfaction Questionnaire for Medication (TSQM), a validated generic measure of treatment satisfaction consisting of 14 Likert-response items comprising four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. The TSQM was completed at baseline and at Week 8. The TSQM consists of 13 items that made up three specific scales (Effectiveness, Side effects, Convenience) and one global satisfaction scale. TSQM items are scaled using either a 5-point or 7-point scale. Five-point scales are used for unidimensional continua (e.g. extremely satisfied to not at all), while 7-point scales are used for bipolar continua (e.g., extremely positive to extremely negative. Non-neutral midpoints are used for 7-point scales, resulting in a greater range of positive response options than negative options for these items. Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.
- Subject Responses to the Patient Impression of Change Questionnaire (Administered at Week 8 Only) [ Time Frame: Week 8 ]A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.
|Study Start Date:||February 2007|
|Study Completion Date:||March 2011|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
IV treprostinil continuous infusion via Crono Five infusion pump.
rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
Other Name: RemodulinDevice: Crono Five ambulatory pump
Used for administration of IV Remodulin (treprostinil)
Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH, and to improve health related quality of life (HRQOL).
Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the intravenous (IV) and subcutaneous (SC) routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension from the CADD legacy pump to a smaller pump called the Crono Five.
Participation in this study will last approximately 10 weeks. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, exercise tests and patient questionnaires. Participants will have 4 visits during the study and will spend at least 1 night in the hospital.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00439946
|United States, California|
|University of California San Francisco (UCSF) Medical Center|
|San Francisco, California, United States, 94143|
|United States, New York|
|THE NEW YORK-PRESBYTERIAN HOSPITAL Weill Cornell Medical Center|
|New York, New York, United States, 10065|
|United States, Oklahoma|
|Integris Baptist Medical Center|
|Oklahoma City, Oklahoma, United States, 73122|
|Principal Investigator:||Remzi Bag, MD||INTEGRIS Baptist Medical Center|
|Principal Investigator:||Evelyn Horn, MD||Weill Medical College of Cornell University|
|Principal Investigator:||Teresa DeMarco, MD||University of California, San Francisco|